Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Slides
Videos-PodcastsVideos & Podcasts

Quicksearch

OP11: Expanded genome-wide association study of Inflammatory Bowel Disease identifies 174 novel loci and directly implicates new genes in disease susceptibilityECCO'22
Year: 2022
Authors: Fachal, L.(1);the International IBD Genetics Consortium, O.B.O.(1);
(1)Wellcome Sanger Institute, Human Genetics, Hinxton, United Kingdom;on behalf of the International IBD Genetics Consortium
OP12: Segmental vs Total Colectomy for Crohn’s Disease of the colon in the biologic era. Results from the SCOTCH international, multicentric studyECCO'22
Year: 2022
Authors: PellinoMD- PhD- FRCS- FEBS Coloproctology- FA, G.(1);Rottoli, M.(2);Mineccia, M.(3);Frontali, A.(4);Celentano, V.(5);Colombo, F.(6);Ardizzone, S.(7);Martí, M.(8);Espín-Basany, E.(8);Ferrero, A.(9);Panis, Y.(10);Poggioli, G.(11);Sampietro, G.M.(12);
(1)Università degli Studi della Campania @Luigi Vanvitelli@, Department of Advanced Medical and Surgical Sciences, Naples, Italy;(2)Alma Mater Studiorum University of Bologna- Sant’Orsola – Malpighi Hospital, Surgery of the Alimentary Tract- Department of Medical and Surgical Sciences-, Bologna, Italy;(3)Ospedale Mauriziano “Umberto I”, Division of General and Oncologic Surgery-, Torino, Italy;(4)Hôpital Beaujon, Service de Chirurgie Colorectale Pôle des Maladies de l'Appareil Digestif PMAD, Clichy, France;(5)Portsmouth Hospitals NHS Trust- University of Portsmouth, Colorectal Surgery, Portsmouth, United Kingdom;(6)“Luigi Sacco” University Hospital, Division of General Surgery-, Milano, Italy;(7)“Luigi Sacco” University Hospital, Division of Gastroentrology-, Milano, Italy;(8)Vall d'Hebron University Hospital, Colorectal Surgery, Barcelona, Spain;(9)Ospedale Mauriziano “Umberto I”., Division of General and Oncologic Surgery-, Torino, Italy;(10)Hôpital Beaujon., Service de Chirurgie Colorectale Pôle des Maladies de l'Appareil Digestif PMAD, Clichy, France;(11)Alma Mater Studiorum University of Bologna- Sant’Orsola – Malpighi Hospital, Surgery of the Alimentary Tract- Department of Medical and Surgical Sciences, Bologna, Italy;(12)ASST Rhodense- Rho Memorial Hospital, Division of General and HPB Surgery, Rho, Italy;
OP13: Modified 2-stage vs. 3-stage ileal pouch-anal anastomosis result in equivalent long-term functional outcomes and pouch survival: A matched-pair analysisECCO'22
Year: 2022
Authors: HolubarMD- MS, S.(1);Prien, C.(1);Jia, X.(2);Liska, D.(1);Kessler, H.(1);Valente, M.(1);Lightner, A.(1);Gorgun, E.(1);Hull, T.(1);Steele, S.(1);
(1)Cleveland Clinic, Department of Colon & Rectal Surgery, Cleveland, United States;(2)Cleveland Clinic, Department of Quantitative Health Sciences, Cleveland, United States;
OP14: Interpreting genome-wide association studies of Inflammatory Bowel Disease through the lens of single-cell sequencingECCO'22
Year: 2022
Authors: Krzak, M.(1);Taylor, L.(1);Alegbe, T.(1);Ghouraba, M.(1);Strickland, M.(1);Przybilla, M.(1);Noell, G.(1);Iyer, V.(1);Cheam, A.X.(2);Matte, J.(1);Parkes, M.(3);McIntyre, R.(1);Raine, T.(3);Anderson, C.(1);
(1)Sanger Institute, Genomics of inflammation and immunity, Hinxton, United Kingdom;(2)Cambridge University, UK Dementia Research Institute, Cambridge, United Kingdom;(3)Addenbrooke’s Hospital, Department of Gastroenterology, Cambridge, United Kingdom;
OP15: A new simplified histology artificial intelligence system for accurate assessment of remission in Ulcerative ColitisECCO'22
Year: 2022
Authors: Villanacci, V.(1);Parigi, T.L.(2,3);Del Amor, R.(4);Mesguer Esbrì, P.(4);Gui, X.(5);Bazarova, A.(6);Bhandari, P.(7);Bisschops, R.(8);Danese, S.(9);De Hertogh, G.(8);Ferraz, J.G.(10);Götz, M.(11);Grisan, E.(12);Hayee, B.(13);Kiesslich, R.(14);Lazarev, M.(15);Mandelli, G.(1);Monica, M.A.T.(1);Panaccione, R.(10);Parra-Blanco, A.(16);Pastorelli, L.(17);Rath, T.(18);Røyset, E.S.(19);Shivaji, U.(3);Tontini, G.E.(17);Vieth, M.(20);Zardo, D.(21);Ghosh, S.(22);Naranjo, V.(4);Iacucci, M.(3);
(1)ASST Spedali Civili- University of Brescia, Institute of Pathology, Brescia, Italy;(2)Humanitas Research Hospital, Department of Biomedical Sciences, Milano, Italy;(3)University of Birmingham, Immunology and Immunotherapy, Birmingham, United Kingdom;(4)Universitat Politécnica de Valéncia, Instituto de Investigación e Innovación en Bioingeniería- I3B, Valencia, Spain;(5)University of Washington School of Medicine, Department of Laboratory Medicine and Pathology, Seattle, United States;(6)University of Cologne, Institute for Biological Physics, Cologne, Germany;(7)Queen Alexandra Hospital, Department of Gastroenterology, Portsmouth, United Kingdom;(8)University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium;(9)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(10)University of Calgary Cumming School of Medicine, Division of Gastroenterology and Hepatology, Calgary, Canada;(11)Klinikum Böblingen, Division of Gastroenterology, Böblingen, Germany;(12)London South Bank University, School of Engineering, London, United Kingdom;(13)King’s College Hospital, King’s Health Partners Institute of Therapeutic Endoscopy, London, United Kingdom;(14)Helios HSK Wiesbaden, Department of Gastroenterology, Wiesbaden, Germany;(15)Johns Hopkins Hospital, Division of Gastroenterology and Hepatology, Baltimore, United States;(16)University of Nottingham, Department of Gastroenterology, Nottingham, United Kingdom;(17)University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy;(18)University of Erlangen, Department of Gastroenterology, Nuremberg, Germany;(19)Norwegian University of Science and Technology, Department of Clinical and Molecular Medicine, Trondheim, Norway;(20)Friedrich-Alexander University, Institute of Pathology- Klinikum Bayreuth-, Nuremberg, Germany;(21)University Hospitals Birmingham NHS Trust, Department of Cellular Pathology, Birmingham, United Kingdom;(22)University College Cork, Department of Medicine, Cork, Ireland;
OP16: The first virtual chromoendoscopy artificial intelligence system to detect endoscopic and histologic remission in Ulcerative ColitisECCO'22
Year: 2022
Authors: Iacucci, M.(1);Cannatelli, R.(2);Parigi, T.L.(1,3);Buda, A.(4);Labarile, N.(5);Nardone, O.M.(6);Tontini, G.E.(7);Rimondi, A.(7);Bazarova, A.(8);Bhandari, P.(9);Bisschops, R.(10);De Hertogh, G.(10);Del Amor, R.(11);Ferraz, J.G.(12);Goetz, M.(13);Gui, X.(14);Hayee, B.(15);Kiesslich, R.(16);Lazarev, M.(17);Naranjo, V.(11);Panaccione, R.(12);Parra-Blanco, A.(18);Pastorelli, L.(19);Rath, T.(20);Røyset, E.S.(21);Vieth, M.(22);Villanacci, V.(23);Zardo, D.(24);Ghosh, S.(25);Grisan, E.(26,27);
(1)University of Birmingham, Immunology and Immunotherapy, Birmingham, United Kingdom;(2)ASST Fatebenefratelli Sacco, Department of Gastroenterology, Milan, Italy;(3)Humanitas Research Hospital, Department of Biomedical Sciences, Milano, Italy;(4)Ospedale di Feltre, Digestive Endoscopy, Feltre BL, Italy;(5)National Institue of Research @Saverio De Bellis@, Section of Gastroenterology II, Castellana Grotte, Italy;(6)Federico II University, Department of Gastroenterology, Naples, Italy;(7)University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy;(8)University of Cologne, Institute for Biological Physics, Cologne, Germany;(9)Queen Alexandra Hospital, Department of Gastroenterology, Portsmouth, United Kingdom;(10)University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium;(11)Universitat Politécnica de Valéncia, Instituto de Investigación e Innovación en Bioingeniería- I3B, Valencia, Spain;(12)University of Calgary Cumming School of Medicine, Department of Gastroenterology, Calgary, Canada;(13)Klinikum Böblingen, Division of Gastroenterology, Böblingen, Germany;(14)University of Washington School of Medicine, Department of Laboratory Medicine and Pathology, Seattle, United States;(15)King’s College Hospital, King’s Health Partners Institute of Therapeutic Endoscopy, London, United Kingdom;(16)Helios HSK Wiesbaden, Department of Gastroenterology, Wiesbaden, Germany;(17)John Hopkins Hospital, Department of Gastroenterology, Baltimore, United States;(18)University of Nottingham, Department of Gastroenterology, Nottingham, United Kingdom;(19)IRCCS Policlinico San Donato, Department of Gastroenterology, Milan, Italy;(20)University of Erlangen, Department of Gastroenterology, Nuremberg, Germany;(21)Norwegian University of Science and Technology, Department of Clinical and Molecular Medicine, Trondheim, Norway;(22)Klinikum Bayreuth- Friedrich-Alexander University, Institute of Pathology, Erlangen-Nuremberg, Germany;(23)ASST Spedali Civili, Institute of Pathology, Brescia, Italy;(24)University Hospitals Birmingham NHS Trust, Department of Cellular Pathology, Birmingham, United Kingdom;(25)University of Cork, School of Medicine, Cork, Ireland;(26)London South Bank University- London- UK, School of Engineering, London, United Kingdom;(27)University of Padova, Department of Information Engineering, Padova, Italy;
OP17: Maintenance phase propensity score adjusted effectiveness and persistence at week-52 in biologic-naïve Ulcerative Colitis patients treated with vedolizumab or anti-TNF (VEDO IBD-study)ECCO'22
Year: 2022
Authors: Plachta-Danielzik, S.(1);di Giuseppe, R.(2);Bokemeyer, B.(3);Efken, P.(4);Mohl, W.(5);Krause, T.(6);Hoffstadt, M.(7);Ehehalt, R.(8);Trentmann, L.(9);Schweitzer, A.(10);Jessen, P.(11);Franzenburg, S.(1);Hartmann, P.(4);Schreiber, S.(12);
(1)Kompetenznetz Darmerkrankungen, Studienabteilung, Kiel, Germany;(2)Kompetenznetz Darmerkrankungen, Statistics and Biometry, Kiel, Germany;(3)Interdisciplinary Crohn Colitis Centre Minden, Crohn Colitis Centre, Minden, Germany;(4)Gastroenterology Practice, Gastroenterology, Minden, Germany;(5)Gastroenterology Practice, Gastroenterology, Saarbrücken, Germany;(6)Gastroenterology Practice, Gastroenterology, Kassel, Germany;(7)Gastroenterology Practice, Gastroenterology, Iserlohn, Germany;(8)Gastroenterology Practice, Gastroenterology, Heidelberg, Germany;(9)Gastroenterology Practice, Gastroenterology, Bremen, Germany;(10)Gastroenterology Practice, Gastroenterology, Münster, Germany;(11)Gemeinschaftspraxis im Medicum, Gastroenterology, Altenholz, Germany;(12)Clinic of General Internal Medicine I, University Hospital Schleswig-Holstein- Campus Kiel, Kiel, Germany;
OP18: Efficacy and safety of filgotinib for the treatment of perianal fistulizing Crohn’s Disease: Results from the phase 2 DIVERGENCE 2 studyECCO'22
Year: 2022
Authors: Reinisch , W.(1);Colombel , J.F.(2);D’Haens , G.R.(3);Rimola , J.(4);DeHaas-Amatsaleh , A.(5);McKevitt , M.(6);Ren , X.(6);Serone , A.(6);Schwartz , D.A.(7);Gecse , K.B.(3);
(1)Medical University of Vienna, Department of Internal Medicine and Gastroenterology, Vienna, Austria;(2)Icahn School of Medicine at Mount Sinai, The Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(3)Amsterdam University Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(4)Hospital Clinic of Barcelona, Inflammatory Bowel Disease Unit, Department of Radiology, Barcelona, Spain;(5)Galapagos, NV, Mechelen, Belgium;(6)Gilead Sciences, Inc., Foster City, United States;(7)Vanderbilt University Medical Center, Division of Gastroenterology, Hepatology and Nutrition, Nashville, United States;
OP19: Classifying perianal fistulising Crohn’s Disease: An expert-consensus to guide decision-making in daily practice and clinical trialsECCO'22
Year: 2022
Authors: Geldof, J.(1);Iqbal, N.(2);LeBlanc, J.F.(3);Sawyer, R.(4);Buskens, C.(5);Bemelman, W.(5);Gecse, K.(6);Lundby, L.(7);Lightner, A.L.(8);Danese, S.(9);Spinelli, A.(10);Carvello, M.(10);Faiz, O.(11);Warusavitarne, J.(11);Lung, P.(12);De Looze, D.(13);D’Hoore, A.(14);Vermeire, S.(15);Hart, A.(3);Tozer, P.(16);
(1)UZ Gent, Gastroenterology and Hepatology, Gent, Belgium;(2)St Mark’s Hospital and Academic Institute, Robin Phillips Fistula Research Unit-, London, United Kingdom;(3)St Mark’s Hospital and Academic Institute, IBD unit, London, United Kingdom;(4)St Mark’s Hospital and Academic Institute, patient representative, London, United Kingdom;(5)Amsterdam University Medical Center- Gastroenterology Endocrinology Metabolism Research Institute, Department of Surgery, Amsterdam, The Netherlands;(6)Amsterdam University Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(7)Aarhus University Hospital, Department of Surgery- Pelvic Floor Unit, Aarhus, Denmark;(8)Cleveland Clinic, Center for Regenerative Medicine and Surgery Colorectal Surgery Digestive Disease Institute Inflammation and Immunity Lerner Research Institute Center for Immunotherapy, Cleveland, United States;(9)Vita-Salute San Raffaele University- IRCCS Hospital San Raffaele, Milan, Italy;(10)Humanitas University- IRCCS Humanitas Research Hospital, Department of Biomedical Sciences, Milan, Italy;(11)St Mark’s Hospital and Academic Institute, Department of Colorectal Surgery, London, United Kingdom;(12)St Mark’s Hospital and Academic Institute, Radiology department, London, United Kingdom;(13)University Hospital Ghent, Department of Gastroenterology and Hepatology, Ghent, Belgium;(14)University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium;(15)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(16)St Mark’s Hospital and Academic Institute- and Imperial College, Robin Phillips Fistula Research Unit- Department of Colorectal Surgery-, London, United Kingdom;
OP20: Perianal fistulas are characterised by expansion of interleukin-22 producing invariant natural killer T-cells and CD4+ T-cells which drive dysregulation of the extracellular matrixECCO'22
Year: 2022
Authors: Constable, L.(1,2);Iqbal, N.(3,4);Cozzetto, D.(1);Hart , A.(3,4);Tozer, P.(3,4);Powell, N.(1);
(1)Imperial College London, Metabolism- Digestion and Reproduction, London, United Kingdom;(2)King's College London, Inflammation Biology, London, United Kingdom;(3)St Mark's Hospital and Academic Institute, Robin Phillips Fistula Research Unit, London, United Kingdom;(4)Imperial College London, Surgery and Cancer, London, United Kingdom;
OP21: COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumabECCO'22
Year: 2022
Authors: Alexander, J.(1,2);Kennedy, N.(3,4);Ibraheim, H.(1,2);Anandabaskaran, S.(1,5);Saifuddin, A.(1,5);Castro Seoane, R.(1);Liu, Z.(1);Nice, R.(4,6);Bewshea, C.(4);D'Mello, A.(7);Constable, L.(1);Jones, G.R.(8,9);Balarajah, S.(1,2);Fiorentino, F.(10);Sebastian, S.(11,12);Irving, P.M.(13,14);Hicks, L.(1,2);Williams, H.(1,2);Kent, A.(15);Linger, R.(16);King, R.(16);Parkes, M.(16,17);Kok, K.(18);Patel, K.(19);Altmann, D.(20);Boyton, R.(21);Goodhand, J.(3,4);Hart, A.(5);Lees, C.(8,9);Ahmad, T.(3,4);Powell, N.(1,2);
(1)Imperial College London, Metabolism- Digestion & Reproduction, London, United Kingdom;(2)Imperial College Healthcare NHS Trust, Gastroenterology, London, United Kingdom;(3)Royal Devon and Exeter NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom;(4)University of Exeter, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, United Kingdom;(5)St Marks Hospital and Academic Institute, Gastroenterology, London, United Kingdom;(6)Royal Devon and Exeter NHS Foundation Trust, Biochemistry- Exeter Clinical Laboratory International, Exeter, United Kingdom;(7)Imperial College Healthcare NHS Trust, Medicine & Integrated Care, London, United Kingdom;(8)Western General Hospital - NHS Lothian, Gastroenterology, Edinburgh, United Kingdom;(9)The University of Edinburgh, Centre for Inflammation Research - The Queen’s Medical Research Institute, Edinburgh, United Kingdom;(10)Imperial College London, Department of Surgery and Cancer, London, United Kingdom;(11)Hull University Teaching Hospitals NHS Trust, Gastroenterology, Hull, United Kingdom;(12)University of Hull, Hull York Medical School, Hull, United Kingdom;(13)Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;(14)King's College London, School of Immunology & Microbial Sciences, London, United Kingdom;(15)King's College Hospital, Gastroenterology, London, United Kingdom;(16)University of Cambridge, NIHR Bioresource, Cambridge, United Kingdom;(17)Cambridge University Hospitals NHS Trust, Gastroenterology, Cambridge, United Kingdom;(18)Bart's Health NHS Trust, Gastroenterology, London, United Kingdom;(19)St George's Hospital NHS Trust, Gastroenterology, London, United Kingdom;(20)Imperial College London, Immunology and Inflammation, London, United Kingdom;(21)Imperial College London, Department of Infectious Disease, London, United Kingdom;
OP22: Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patientsECCO'22
Year: 2022
Authors: Lin, S.(1,2);Kennedy, N.A.(1,2);Saifuddin, A.(3,4);Muñoz Sandoval, D.(5);Reynolds, C.J.(5);Seoane, R.C.(6);Kottoor, S.H.(4);Pieper, F.P.(5);Lin, K.M.(5);Butler, D.K.(5);Chanchlani, N.(1,2);Nice, R.(2,7);Chee, D.(1,2);Bewshea, C.(2);Janjua, M.(1,2);McDonald, T.J.(7);Sebastian, S.(8,9);Alexander, J.L.(4,10);Constable, L.(4);Lee, J.C.(11,12,13);Murray, C.D.(11);Hart, A.L.(3);Irving, P.M.(14,15);Jones, G.R.(16,17);Kok, K.B.(18,19);Lamb, C.A.(20,21);Lees, C.W.(16,22);Altmann, D.M.(6);Boyton, R.J.(5,23);Goodhand, J.R.(1,2);Powell, N.(4,10);Ahmad, T.(1,2); CLARITY IBD
(1)Royal Devon and Exeter NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom;(2)University of Exeter, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, United Kingdom;(3)St Marks Hospital and Academic Institute, Gastroenterology, London, United Kingdom;(4)Imperial College London, Metabolism- Digestion and Reproduction, London, United Kingdom;(5)Imperial College London, Infectious Disease, London, United Kingdom;(6)Imperial College London, Immunology and Inflammation, London, United Kingdom;(7)Royal Devon and Exeter NHS Foundation Trust, Biochemistry- Exeter Clinical Laboratory International, Exeter, United Kingdom;(8)Hull University Teaching Hospitals NHS Trust, Gastroenterology, Hull, United Kingdom;(9)University of Hull, Hull York Medical School, Hull, United Kingdom;(10)Imperial College Healthcare NHS Trust, Gastroenterology, London, United Kingdom;(11)Royal Free London NHS Foundation Trust, Gastroenterology, London, United Kingdom;(12)University of Cambridge, Cambridge Institute of Therapeutic Immunology and Infectious Disease- Jeffrey Cheah Biomedical Centre, Cambridge, United Kingdom;(13)The Francis Crick Institute, Genetic Mechanisms of Disease Laboratory, London, United Kingdom;(14)Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;(15)King's College London, School of Immunology & Microbial Sciences, London, United Kingdom;(16)Western General Hospital- NHS Lothian, Gastroenterology, London, United Kingdom;(17)The University of Edinburgh, Centre for Inflammation Research- The Queen’s Medical Research Institute, Edinburgh, United Kingdom;(18)Royal London Hospital- Barts Health NHS Trust, Gastroenterology, London, United Kingdom;(19)Barts and the London School of Medicine- Queen Mary, Centre for Immunobiology- Blizard Institute, London, United Kingdom;(20)Newcastle upon Tyne Hospitals NHS Foundation Trust, Gastroenterology, Newcastle upon Tyne, United Kingdom;(21)Newcastle University, Translational & Clinical Research Institute- Faculty of Medical Sciences, Newcastle upon Tyne, United Kingdom;(22)University of Edinburgh, Institute of Genetic and Molecular Medicine, Edinburgh, United Kingdom;(23)Royal Brompton Hospital and Harefield Hospitals, Lung Division, London, United Kingdom;
OP23: The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12ECCO'22
Year: 2022
Authors: Dignass, A.(1);Rubin, D.(2);Bressler, B.(3);Huang, K.H.(4);Shipitofsky, N.(4);Germinaro, M.(4);Zhang, H.(4);Johanns, J.(4);Feagan, B.(5);Sandborn, W.(6);Sands, B.(7);Hisamatsu, T.(8);Lichtenstein, G.(9);Panes, J.(10);Allegretti , J.(11); QUASAR Investigators
(1)Agaplesion Markus Hospital, Department of Medicine, Frankfurt, Germany;(2)The University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(3)University of British Columbia, Division of Gastroenterology, Vancouver, Canada;(4)Janssen Research & Development- LLC, Immunology, Spring House, United States;(5)Western University, Robarts Clinical Trials, Ontario, Canada;(6)University of California San Diego, Division of Gastroenterology, La Jolla, United States;(7)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(8)Kyorin University, Department of Gastroenterology and Hepatology, Tokyo, Japan;(9)University of Pennsylvania, Department of Medicine- Division of Gastroenterology, Philadelphia, United States;(10)Hospital Clínic de Barcelona, IDIBAPS- CIBERehd, Barcelona, Spain;(11)Brigham and Women’s Hospital Crohn’s and Colitis Center, Division of Gastroenterology- Hepatology and Endoscopy, Boston, United States;
OP24: Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn’s Disease: Week 48 analyses from the phase 2 GALAXI 1 studyECCO'22
Year: 2022
Authors: Danese, S.(1);Panaccione, R.(2);Rubin, D.T.(3);Sands, B.E.(4);Reinisch, W.(5);D'Haens, G.(6);Panés, J.(7);Gonzalez, S.(8);Weisel, K.(8);Sahoo, A.(8);Frustaci, M.E.(8);Yang, Z.(8);Sandborn, W.J.(9);Afzali, A.(10);Hisamatsu, T.(11);Andrews, J.M.(12);Feagan, B.(13); on behalf of the GALAXI-1 investigators
(1)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milano, Italy;(2)University of Calgary, Inflammatory Bowel Disease Group, Calgary, Canada;(3)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(4)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(5)Medical University of Vienna, Div. Gastroenterology & Hepatology, Vienna, Austria;(6)Amsterdam University Medical Centers, Department of Gastroenterology, Amsterdam, The Netherlands;(7)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Department of Gastroenterology, Barcelona, Spain;(8)Janssen Research & Development- LLC, Immunology, Spring House, United States;(9)University of California San Diego, Division of Gastroenterology, La Jolla, United States;(10)The Ohio State University, Wexner Medical Center, Columbus, United States;(11)Kyorin University, Department of Gastroenterology and Hepatology, Tokyo, Japan;(12)Royal Adelaide Hospital & University of Adelaide, Department of Gastroenterology & Hepatology, Adelaide, Australia;(13)Western University and Alimentiv Inc., Department of Gastroenterology, London, Canada;
OP25: Patients with moderate to severe Crohn’s Disease with and without prior biologic failure demonstrate improved endoscopic outcomes with risankizumab: Results from phase 3 induction and maintenance trialsECCO'22
Year: 2022
Authors: Ferrante, M.(1);Cao, Q.(2);Fujii, T.(3);Rausch, A.(4);Neimark, E.(5);Song, A.(6);Wallace, K.(6);Kligys, K.(7);Zhou, Q.(8);Kalabic, J.(9);Feagan, B.G.(10);
(1)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)Sir Run Run Shaw Hospital- Zhejiang University School of Medicine, Department of Gastroenterology, Hangzhou, China;(3)Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan;(4)British Hospital, Gastroenterology Department, Buenos Aires, Argentina;(5)AbbVie, Clinical Development, Worcester, United States;(6)AbbVie, Clinical Development, North Chicago, United States;(7)AbbVie, Medical Affairs, Mettawa, United States;(8)AbbVie, Statistics, North Chicago, United States;(9)AbbVie Deutschland GmbH & Co. KG, Clinical Development, Ludwigshafen, Germany;(10)Western University, Robarts Clinical Trials- Robarts Research Institute, London, Canada;
OP26: Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 studyECCO'22
Year: 2022
Authors: D'Haens, G.(1);Kobayashi, T.(2);Morris, N.(3);Lissoos, T.(3);Hoover, A.(3);Li, X.(3);Arora, V.(3);Milch, C.(3);Sandborn, W.J.(4);Sands, B.E.(5);
(1)Amsterdam University Medical Centers, Gastroenterology, Amsterdam, The Netherlands;(2)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(3)Eli Lilly and Company, Biomedicines, Indianapolis, United States;(4)University of California San Diego, Gastroenterology, San Diego, United States;(5)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;
OP27: A Phase 1 Study Evaluating the Bioequivalence of the Proposed Commercial and Clinical Formulations of Etrasimod 2mg, and the Effect of Food on the Pharmacokinetics of the Proposed Commercial Formulation in Healthy VolunteersECCO'22
Year: 2022
Authors: Lee, C.(1);Ramaiya, A.(1);Tang , Y.(1);Sapone, A.(2);Shan , K.(3);Randle, A.(4);Grundy, J.(1);
(1)Arena Pharmaceuticals- Inc., Nonclinical Dev & Clinical Pharmacology, San Diego, United States;(2)Arena Pharmaceuticals- Inc., Clinical Development, San Diego, United States;(3)Arena Pharmaceuticals- Inc., Biostatistics & Data Mgmt, San Diego, United States;(4)Arena Pharmaceuticals- Inc., Clinical Operations, San Diego, United States;
OP28: A randomized placebo controlled clinical trial with 5-hydroxytryptophan in patients with quiescent Inflammatory Bowel Disease and fatigue (Trp-IBD)ECCO'22
Year: 2022
Authors: Truyens, M.(1,2,3);Lobaton, T.(1,3);Peeters, A.(1);Ferrante, M.(4,5);Vermeire, S.(4,5);Bossuyt, P.(6);Pouillon, L.(6);Dewint, P.(7,8);Cremer, A.(9);Peeters, H.(10);Lambrecht, G.(11);Louis, E.(12);Rahier, J.F.(13);Dewit, O.(14);Muls, V.(15);Holvoet, T.(1,16);Vandermeulen, L.(17);Gonzales, G.B.(2,3,18);Laukens, D.(2,3);De Vos, M.(3);
(1)University Hospital Ghent, Department of Gastroenterology, Ghent, Belgium;(2)Ghent University, VIB center for Inflammation Research IRC, Ghent, Belgium;(3)Ghent University, Department of Internal Medicine and Pediatrics, Ghent, Belgium;(4)KU Leuven, Department of Chronic Diseases- Metabolism and Ageing CHROMETA- Translational Research Center for Gastrointestinal Disorders TARGID, Leuven, Belgium;(5)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(6)Imelda General Hospital, Imelda GI Clinical Research Center, Bonheiden, Belgium;(7)AZ Maria Middelares, Department of Gastroenterology, Ghent, Belgium;(8)UZ Antwerp, Department of Gastroenterology, Antwerp, Belgium;(9)Erasme Hospital, Department of Gastroenterology, Brussels, Belgium;(10)AZ Sint-Lucas, St-Lucas IBD Clinic, Ghent, Belgium;(11)AZ Damiaan, Department of Gastroenterology, Oostende, Belgium;(12)CHU Liège University Hospital, Department of Gastroenterology, Liège, Belgium;(13)CHU UCL Namur, Department of Gastroenterology, Yvoir, Belgium;(14)UCL Saint Luc, Service d’Hépato-Gastroentérologie, Brussels, Belgium;(15)Saint-Pierre University Hospital Center - Université Libre de Bruxelles ULB, Department of Gastroenterology and Endoscopy, Brussels, Belgium;(16)AZ Nikolaas General Hospital, Department of Gastroenterology, Sint-Niklaas, Belgium;(17)Universitair Ziekenhuis Brussel UZ Brussel - Vrije Universiteit Brussel VUB, Department of Gastroenterology-Hepatology, Brussels, Belgium;(18)Wageningen University and Research, Nutrition- Metabolism and Genomics Group - Division of Human Nutrition and Health, Wageningen, Belgium;
OP29: Peripheral blood DNA methylation biomarkers accurately predict clinical- and endoscopic response to vedolizumab in a real-life cohort of Crohn’s Disease patientsECCO'22
Year: 2022
Authors: Joustra, V.(1);Hageman, I.(1,2);Li Yim, A.(2,3);Levin, E.(4,5);Satsangi, J.(6);Adams, A.(6);De Jonge, W.(2);Henneman, P.(3);D'Haens, G.(1); on behalf of the EPIC consortium
(1)Amsterdam UMC- University of Amsterdam, Department of Gastroenterology & Hepatology, Amsterdam, The Netherlands;(2)Amsterdam UMC- University of Amsterdam, Tytgat Institute for Liver and Intestinal Research, Amsterdam, The Netherlands;(3)Amsterdam UMC- University of Amsterdam, Genome Diagnostics Laboratory- Department of Clinical Genetics, Amsterdam, The Netherlands;(4)Horaizon, Bv, Delft, The Netherlands;(5)Amsterdam UMC- University of Amsterdam, Department of Vascular Medicine, Amsterdam, The Netherlands;(6)Oxford University- Hospitals NHS Foundation Trust- John Radcliffe Hospital, Translational Gastroenterology Unit- NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom;
OP30: Upadacitinib modulates inflammatory pathways in gut tissue in patients with Ulcerative Colitis: Transcriptomic profiling from the Phase 2b study, U-ACHIEVEECCO'22
Year: 2022
Authors: Verstockt, B.(1);Blink Polakow, S.(2);Mahi, N.(2);Lee, J.(2);Wang, J.(3);Guay, H.(4);Salas, A.(5);Panés, J.(5);Ungaro, R.C.(6);Vermeire, S.(1);
(1)University Hospitals Leuven & KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)AbbVie Inc, Immunology, North Chicago, United States;(3)AbbVie Inc, Genomic Research Center, Cambridge, United States;(4)AbbVie Inc, Bioresearch Center, Worcester, United States;(5)Hospital Clinic de Barcelona, IDIBAPS CIBERehd, Barcelona, Spain;(6)The Mount Sinai Hospital, Icahn School of Medicine, New York, United States;